Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CPRX Catalyst Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: CPRX
Price (delayed)
$20.96
Market cap
$2.56B
P/E Ratio
12.7
Dividend/share
N/A
EPS
$1.65
Enterprise value
$1.98B
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK
Highlights
The EPS has soared by 175% year-on-year and by 20% since the previous quarter
Catalyst Pharmaceuticals's equity has increased by 41% YoY and by 9% QoQ
Key stats
What are the main financial stats of CPRX
Market
Valuations
Earnings
Shares outstanding
121.98M
Market cap
$2.56B
Enterprise value
$1.98B
Price to earnings (P/E)
12.7
Price to book (P/B)
3.2
Price to sales (P/S)
4.76
EV/EBIT
7.66
EV/EBITDA
6.67
EV/Sales
3.7
Revenue
$534.65M
Gross profit
$460.41M
Operating income
$231.37M
Net income
$197.35M
EBIT
$258.46M
EBITDA
$296.55M
Free cash flow
$267.57M
Per share
Balance sheet
Liquidity
EPS
$1.65
EPS diluted
$1.57
Free cash flow per share
$2.2
Book value per share
$6.54
Revenue per share
$4.4
TBVPS
$6.27
Total assets
$908.87M
Total liabilities
$114.59M
Debt
$2.68M
Equity
$794.28M
Working capital
$574.07M
Debt to equity
0
Current ratio
6.14
Quick ratio
5.84
Net debt/EBITDA
-1.95
Margins
Efficiency
Dividend
EBITDA margin
55.5%
Gross margin
86.1%
Net margin
36.9%
Operating margin
43.3%
Return on assets
24.4%
Return on equity
28.3%
Return on invested capital
400.2%
Return on capital employed
32.4%
Return on sales
48.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CPRX stock price
How has the Catalyst Pharmaceuticals stock price performed over time
Intraday
0.05%
1 week
-1.09%
1 month
-18.98%
1 year
35.66%
YTD
0.43%
QTD
-3.41%
Financial performance
How have Catalyst Pharmaceuticals's revenue and profit performed over time
Revenue
$534.65M
Gross profit
$460.41M
Operating income
$231.37M
Net income
$197.35M
Gross margin
86.1%
Net margin
36.9%
The company's operating income has surged by 195% YoY and by 19% QoQ
Catalyst Pharmaceuticals's net margin has surged by 134% YoY and by 11% QoQ
The operating margin has soared by 128% YoY and by 9% QoQ
The revenue rose by 30% YoY and by 9% QoQ
Price vs fundamentals
How does CPRX's price correlate with its fundamentals
Growth
What is Catalyst Pharmaceuticals's growth rate over time
Valuation
What is Catalyst Pharmaceuticals stock price valuation
P/E
12.7
P/B
3.2
P/S
4.76
EV/EBIT
7.66
EV/EBITDA
6.67
EV/Sales
3.7
The EPS has soared by 175% year-on-year and by 20% since the previous quarter
The stock's P/E is 29% less than its last 4 quarters average of 18.0 and 20% less than its 5-year quarterly average of 15.9
Catalyst Pharmaceuticals's equity has increased by 41% YoY and by 9% QoQ
The stock's price to book (P/B) is 11% less than its 5-year quarterly average of 3.6 and 6% less than its last 4 quarters average of 3.4
The revenue rose by 30% YoY and by 9% QoQ
The price to sales (P/S) is 4.8% lower than the last 4 quarters average of 5.0 and 2.9% lower than the 5-year quarterly average of 4.9
Efficiency
How efficient is Catalyst Pharmaceuticals business performance
The ROIC has soared by 192% year-on-year and by 21% since the previous quarter
The ROS has soared by 130% year-on-year and by 10% since the previous quarter
CPRX's return on assets has surged by 85% year-on-year and by 11% since the previous quarter
The ROE has soared by 81% YoY and by 11% from the previous quarter
Dividends
What is CPRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CPRX.
Financial health
How did Catalyst Pharmaceuticals financials performed over time
The total assets is up by 41% year-on-year and by 7% since the previous quarter
The total liabilities rose by 34% YoY but it fell by 7% QoQ
Catalyst Pharmaceuticals's debt is 100% lower than its equity
CPRX's debt to equity has dropped by 100% year-on-year
Catalyst Pharmaceuticals's equity has increased by 41% YoY and by 9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.